Revised SPC: Xaluprine (mercaptopurine monohydrate) 20 mg/ml oral suspension

Portal hypertension, nodular regenerative hyperplasia and sinusoidal obstruction syndrome added as adverse effects of treatment with unknown frequency (reported in patients with inflammatory bowel disease – an unlicensed indication).

Source:

electronic Medicines compendium